×
International Stem Cell Inventory 2010-2024 | ISCO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
International Stem Cell inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
View More
International Stem Cell Inventory 2010-2024 | ISCO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
International Stem Cell inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$158.3B
Bristol Myers Squibb (BMY)
$119.4B
Vertex Pharmaceuticals (VRTX)
$116.1B
Gilead Sciences (GILD)
$112.4B
CSL (CSLLY)
$87.2B
Regeneron Pharmaceuticals (REGN)
$81.1B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$31.6B
BioNTech SE (BNTX)
$27.1B
Biogen (BIIB)
$23B
Illumina (ILMN)
$22.2B
BeiGene (BGNE)
$18.6B
Moderna (MRNA)
$15.8B
Incyte (INCY)
$13.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$13.1B
BioMarin Pharmaceutical (BMRN)
$12.2B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.8B
Revolution Medicines (RVMD)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8B
Ascendis Pharma (ASND)
$7.9B